Sophia Genetics (NASDAQ:SOPH) Stock, Quote.Headers.trade-ideas

Sophia Genetics

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

Movers

News

Intraday Update

Markets

Trading Ideas

ASTI

ASTS

AWIN

BNAI

BNZI

CAVA

CHWY

CNEY

CRKN

FFIE

GENE

GYRE

HLTH

IKNA

IMVT

Kintara Therapeutics, Inc. - Common Stock

KTRA

LUCY

MBIO

MRVI

NEON

ONFO

OOMA

POAI

RSLS

SCPX

SMLR

SOBR

SOPH

SRDX

STSS

SYTA

TANH

TITN

TOST

VERU

Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

MOMO

NABL

Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie &amp; Fitch And Other Big Stocks Moving Higher On Wednesday

Penny Stocks

Small Cap

AFMD

AISP

APEI

BASE

BIAF

BYSI

CERS

CETX

CMAX

CRWD

CXDO

DADA

DAVE

ENCP

FULC

GNPX

GRFS

HIPO

HSCS

IFBD

INFN

JAGX

LTRN

LYFT

MEDS

MNTS

MSTR

NEPT

NKGN

OCEA

PHUN

ROOT

RVSN

SBFM

SGHC

TTEC

UNFI

VINC

XRTX

Shares of  United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Sophia Genetics SA

Bitcoin and Ethereum ETFs recorded significant net outflows, despite the <a href="https://www.benzinga.com/markets/equities/24/09/40926298/dow-jumps-over-100-points-fed-cuts-interest-rates-by-0-5#google_vignette">U.S. Federal Reserve's announcement</a> of a 50 basis point rate cut.
What Happened: Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) spot ETFs had a net outflow of $52.827 million, the first outflow after four days of inflows. Grayscale's Bitcoin ETF (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#OTC">GBTC</a>) saw an additional $8.1347 million outflow.
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) spot ETFs followed suit with a total net outflow of $9.738 million, while Grayscale's Ethereum ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETHE#NYSE">ETHE</a>) lost $14.6629 million. However, BlackRock's Ethereum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>) saw a net inflow of $4.9249 million, standing out from the overall trend.
QCP Capital explained that the Fed's decision to cut rates, while expected by many, caused a shift towards riskier assets like cryptocurrencies. 
Despite Federal Reserve Chair Jerome Powell leaving uncertainty about future rate cuts, the move has led to increased optimism in the markets, reflected in the U.S. treasury market.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40934959/anthony-scaramucci-says-donald-trump-is-a-polarizing-person-but-pulling-democrats-along-on">Anthony Scaramucci Says Donald Trump Is A &#8216;Polarizing Person&#8217; But &#8216;Pulling Democrats Along&#8217; On Crypto, Working On Distancing Kamala Harris &#8216;Away From Gary Gensler&#8217;</a>
QCP also noted that Bitcoin's price rose from $59,000 to $62,000, while Ethereum is trading near $2,400 following the Fed's announcement.
Greekslive also <a href="https://x.com/GreeksLive/status/1836590118968475721?s=19">highlighted</a> that the Fed's rate cut exceeded some expectations, pushing cryptocurrency prices higher while U.S. stocks lagged.
They pointed out that investors' expectations for market volatility have dropped significantly, with short-term selling pressure easing. 
However, they also cautioned that with upcoming interest rate decisions in November and December, and the U.S. election on the horizon, market volatility could increase again later this year.
What&#8217;s Next: The influence of <a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a> is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40927528/microstrategy-raises-875m-in-convertible-notes-plans-further-bitcoin-purchases">MicroStrategy Raises $875M In Convertible Notes, Plans Further Bitcoin Purchases</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

ETHA

ETHE

GBTC

Bitcoin, Ethereum ETFs See Over $50M Net Outflows Despite Fed's 50 Bps Rate Cut

Small Cap Consumer Research analyst Eric Beder reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $3 price target.

Price Target

Reiteration

Analyst Ratings

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $3 Price Target

WIIM

EWTX

Edgewise Therapeutics shares are trading higher after the company announced  top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCMtrial in patients with obstructive HCM.

Baird analyst Colin Sebastian maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Outperform and maintains $170 price target.

Baird Maintains Outperform on Electronic Arts, Maintains $170 Price Target

Squirrel Enlivened International Co., Ltd ("Squirrel Cayman"), a brand marketing and strategy consulting company, and Horizon Space Acquisition I Corp. ("HSPO") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSPO#NASDAQ">HSPO</a>), a publicly traded special purpose acquisition company, today announced the confidential submission of a draft Registration Statement on Form F-4, including a preliminary proxy statement (the "Registration Statement") to the U.S. Securities and Exchange Commission (the "SEC") on September 19, 2024 with respect to their previously announced proposed business combination (the "Business Combination") pursuant to the business combination agreement dated September 16, 2024 ("Business Combination Agreement").
The Registration Statement contains a preliminary proxy statement and prospectus in connection with the Business Combination Agreement and proposed Business Combination. While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about Squirrel Cayman, HSPO, and the Business Combination.
Consummation of the Business Combination is subject to the satisfaction or waiver by the respective parties of a number of conditions, including but not limited to, the approval of the Business Combination Agreement and the Business Combination by HSPO's shareholders.
Upon the completion of the Business Combination, shares of Squirrel Cayman will be listed on The Nasdaq Stock Market LLC ("Nasdaq").

HSPO

Horizon Space Acquisition I Corp. Announces Confidential Submission Of Registration Statement To The SEC For Proposed Business Combination With Squirrel Enlivened International Co., Ltd.

CACI

CACI Secures $273M Five-Year Task Order To Provide Intelligence Expertise To U.S. Central Command, Aiding In Protection Against Foreign Adversarial Threats

Guidance

United States Steel Says Challenging Pricing Dynamics Are Being Offset In Part By The Benefits Of Balanced And Diverse Order Books In The North American Flat-Rolled Segment In Europe, Co. Says Experiencing A Softening Demand Environment

United States Steel Sees Q3 Adj. EPS $0.44-$0.48, Adj. EBITDA ~$300M

Stock Split

OTRK

Ontrak Announces 1-For-15 Reverse Stock Split Effective September 23, 2024

New locations in Bucharest, Romania, Buffalo, New York, and Leicester, UK, aim to help clients explore opportunities in generative AI, hybrid cloud and other Microsoft technologies to transform their business
ARMONK, N.Y., Sept. 19, 2024 /PRNewswire/ -- Today, IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) and Microsoft announced the official opening of three new IBM-Microsoft Experience Zones within IBM's Client Innovation Centers. These Experience Zones are designed to help global clients across industries, such as financial services, government, healthcare, industrial, manufacturing and consumer packed goods (CPG), find new ways to derive value from <a href="https://www.ibm.com/topics/artificial-intelligence">generative AI</a>, <a href="https://www.ibm.com/topics/hybrid-cloud">hybrid cloud</a> and other Microsoft products and technologies.

MSFT

IBM And Microsoft Open 3 New Experience Zones To Provide Global Clients With More Hands-On Access To Cloud And Generative AI Solutions

Vistra shares are trading higher after the company announced that it has executed definitive agreements with affiliates of Nuveen Asset Management and Avenue Capital Management II to acquire their combined 15% equity interest in Vistra Vision.

Milestone enables Vodafone Ireland to deliver superior customer experiences and operational excellence through a consolidated customer view and simplified architecture
JERSEY CITY, NJ / ACCESSWIRE / September 19, 2024 / Amdocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOX#NASDAQ">DOX</a>), a leading provider of software and services to communications and media companies, today announced the successful completion of a unified single business support system (BSS) and operations support system (OSS) platform transformation for Vodafone Ireland, integrating mobile and fixed communication services into a single, streamlined system, enhancing operational efficiency and customer experience.
The new platform provides a consolidated customer view, empowering front-line agents to make informed decisions, reducing errors, and streamlining processes. This transformation leads to a more automated, quicker, and consistent customer journey.

Vodafone Ireland Completes Unified Platform Transformation With Amdocs, Enhancing Customer Experience And Operational Efficiency

In July 2021, Alector Entered Into A Collaboration With GSK For Global Development And Commercialization Of Progranulin-Elevating Monoclonal Antibodies, Receiving $700M Upfront And Eligible For Up To $1.5B In Milestone Payments; Companies Will Share U.S. Profits Equally, With Alector Receiving Double-Digit Royalties Internationally

Biotech

General

ALEC

Alector Presents Baseline Data For INFRONT-3 Phase 3 Trial Of Latozinemab At ISFTD 2024, Targeting Frontotemporal Dementia With Progranulin Gene Mutation (FTD-GRN)

BLDR

Builders FirstSource shares are trading higher. The company appointed Peter Jackson as its next President and CEO and Pete Beckmann As CFO.

MBLY

Mobileye shares are trading higher after Intel reportedly said it does not have plans to divest a majority interest in the company.

− Presentations Include New Data from the TAK-861-2001 Phase 2b Trial in Narcolepsy Type 1 Highlighting Impact on Daily Functioning Including Cognition and Sleep Quality
− Data from Long-Term Extension Study will also be Presented
− Phase 3 Trial of an Orexin Agonist for Narcolepsy Type 1 Now Enrolling Patients Globally
Takeda((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&amp;,%20esheet=54124174&amp;,%20newsitemid=20240919392083&amp;,%20lan=en-US&amp;,%20anchor=TSE%3A4502%2FNYSE%3ATAK&amp;,%20index=1&amp;,%20NYSE:%3Ca%20class=">TAK</a>) will present additional data from the Phase 2b trials (TAK-861-2001,TAK-861-2002) and long-term extension (LTE) study (TAK-861-2003) of TAK-861 in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society (ESRS), being held September 24-27, 2024 in Seville, Spain. TAK-861 is an investigational oral orexin receptor 2 (OX2R) selective-agonist designed to address the orexin deficiency in NT1 by selectively stimulating the orexin receptor 2. TAK-861 has the potential to be the first treatment to address the underlying pathophysiology of NT1. Based on the positive Phase 2b trial results, Takeda has initiated the FirstLight Study, a global Phase 3 trial evaluating the efficacy and safety of TAK-861 in adults with NT1.

Takeda To Present Additional Clinical Trial Study Data Highlighting The Impact Of Orexin Agonist TAK-861 On The Burden Of Narcolepsy At Sleep Europe 2024

PGNY

Progyny shares are trading lower after a client elected to exercise an option to terminate its services agreement with the company.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fastriatx.com%2F&amp;esheet=54124067&amp;newsitemid=20240919236987&amp;lan=en-US&amp;anchor=Astria+Therapeutics%2C+Inc.&amp;index=1&amp;md5=1b6ed34c07d2e6ec049db7d767adfac4">Astria Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024.
Raffi Tachdjian, M.D., MPH, Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), will present a poster titled "ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes." The poster will be presented in e-poster showcase six on Thursday, September 26 at 4:20pm CEST.

ATXS

Astria Therapeutics To Present Initial Navenibart ALPHA-STAR Data At The Upcoming European Academy Of Dermatology And Venereology Congress

CBRL

Cracker Barrel Old Country Store Sees FY25 Total Revenue Of $3.4B-$3.5B Vs. $3.45B Estimate

ALGS

Aligos Therapeutics Announces Results From Phase 2a HERALD  Study Showing ALG-055009 Dose Groups Met Primary Endpoint With Statistically Significant Reductions In Liver Fat At Week 12

In a report released on June 21, Conor McNamara from RBC Capital maintained a Buy rating on SOPHiA GENETICS (SOPH – Research Report), with a price ...

RBC Capital Sticks to Their Buy Rating for SOPHiA GENETICS (SOPH)

SOPHiA GENETICS (SOPH) has released an update. SOPHiA GENETICS SA, with its base in Rolle, Canton of Vaud, Switzerland, focuses on the management a...

SOPHiA GENETICS: Versatile Corporate Structure and Global Ambitions

SOPHiA Genetics reports Q2 results

SOPHiA GENETICS (SOPH) has released an update. SOPHiA GENETICS SA has reported its unaudited interim condensed consolidated financial results, indi...

SOPHiA GENETICS Reports Mid-Year Financials

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sophia Genetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/soph-stock-quote/">SOPH</a>) just reported results for the second quarter of 2024.<ul><li>Sophia Genetics reported earnings per share of -23 cents. This was above the analyst estimate for EPS of -28 cents.</li><li>The company reported revenue of $15.81 million.</li><li>This was 9.15% worse than the analyst estimate for revenue of $17.40 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/soph-stock-earnings-sophia-genetics-for-q2-of-2024/">SOPH Stock Earnings: Sophia Genetics Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SOPH Stock Earnings: Sophia Genetics Beats EPS, Misses Revenue for Q2 2024

SOPHiA GENETICS SA (SOPH) Q2 2024 Earnings Call Transcript

In a report released today, Daniel Brennan from TD Cowen maintained a Buy rating on SOPHiA GENETICS (SOPH – Research Report). The company's shares ...

TD Cowen Sticks to Their Buy Rating for SOPHiA GENETICS (SOPH)

Morgan Stanley analyst Tejas Savant downgraded the rating on SOPHiA GENETICS (SOPH – Research Report) to a Hold today, setting a price target of $5...

Hold Rating on SOPHiA GENETICS Amidst Q2 Revenue Shortfall and Balanced Risk/Reward Outlook

Tracking Al Gore's Generation Investment Management Portfolio - Q2 2024 Update

TD Cowen analyst Daniel Brennan maintained a Buy rating on SOPHiA GENETICS (SOPH – Research Report) today. The company's shares closed yesterday at...

SOPHiA GENETICS (SOPH) Gets a Buy from TD Cowen

AMZN

CBRE

CLVT

FRSH

HSIC

MELI

NTNX

RELY

SCHW

TRMB

TSMWF

TWLO

TYGO

WDAY

XRAY

Press Releases

SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA DDM™

Earnings

SOPHiA GENETICS Reports Second Quarter 2024 Results

SOPHiA DDM™ Platform Certified Under IVDR

SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference

SOPHiA GENETICS Unveils New Generation of the SOPHiA DDMTM Platform at Morgan Stanley Healthcare Conference 2024

SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

Contracts

SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024

SOPHiA GENETICS Announces Poster Presentations at ESMO 2024

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Sophia Genetics

Sophia Genetics (SOPH) Forecast

Sophia Genetics (NASDAQ:SOPH) Stock, Quote.Headers.trade-ideas